Generalized Myasthenia Gravis Clinical Trials

15 studies are recruiting for generalized myasthenia gravis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

   This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects a…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Profound Research LLC - Carlsbad, Carlsbad, California

   Locations

   32 in total

   Run by

   argenx

   See if you can join NCT07284420 on ClinicalTrials.gov

2. ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

   ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Profound Research LLC - Carlsbad, Carlsbad, California

   Locations

   35 in total

   Run by

   argenx

   See if you can join NCT07294170 on ClinicalTrials.gov

3. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

   The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of o…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Arizona Neuroscience Research, LLC, Phoenix, Arizona

   Locations

   153 in total

   Run by

   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

   See if you can join NCT06463587 on ClinicalTrials.gov

4. A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

   The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to <18 years. The primary goal is to confirm an appropriate dose of efgartigimod PH20 SC for pediatric…

   Stage

   Phase 2

   Ages

   2 to 17

   Site

   Carolinas HealthCare System Neurosciences Institute - Neurology, Charlotte, North Carolina

   Locations

   21 in total

   Run by

   argenx

   See if you can join NCT06392386 on ClinicalTrials.gov

5. A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

   The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of inebilizumab administered in pediatric participants with gMG.

   Stage

   Phase 2

   Ages

   2 to 17

   Site

   The Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   9 in total

   Run by

   Amgen

   See if you can join NCT06987539 on ClinicalTrials.gov

6. A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

   The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

   Stage

   Phase 2

   Ages

   12 to 17

   Site

   Mg0014 40144, Milan,

   Locations

   9 in total

   Run by

   UCB Biopharma SRL

   See if you can join NCT06055959 on ClinicalTrials.gov

7. Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

   The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

   Stage

   Phase 3

   Ages

   18 to 80

   Site

   Site Number - 1056, Huntsville, Alabama

   Locations

   88 in total

   Run by

   Immunovant Sciences GmbH

   See if you can join NCT07039916 on ClinicalTrials.gov

8. KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

   A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Ronald Reagan UCLA Medical Center, Los Angeles, California

   Locations

   22 in total

   Run by

   Kyverna Therapeutics

   See if you can join NCT06193889 on ClinicalTrials.gov

9. A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

   A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Neuromuscular Research Center, Phoenix, Arizona

   Locations

   130 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06744920 on ClinicalTrials.gov

10. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

    The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    HonorHealth Neurology - Bob Bové Neuroscience Institute, Scottsdale, Arizona

    Locations

    111 in total

    Run by

    Vor Biopharma

    See if you can join NCT06456580 on ClinicalTrials.gov

11. A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

    This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated w…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Research Site, Raleigh, North Carolina

    Locations

    12 in total

    Run by

    Alexion Pharmaceuticals, Inc.

    See if you can join NCT07221838 on ClinicalTrials.gov

12. PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

    The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

    Stage

    Phase 3

    Ages

    6 to 17

    Site

    Research Site, Washington D.C., District of Columbia

    Locations

    13 in total

    Run by

    Alexion Pharmaceuticals, Inc.

    See if you can join NCT06607627 on ClinicalTrials.gov

13. Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

    Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Clinical Trial Site, Birmingham, Alabama

    Locations

    51 in total

    Run by

    Alexion Pharmaceuticals, Inc.

    See if you can join NCT04202341 on ClinicalTrials.gov

14. Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

    The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximately 28 weeks * The tre…

    Stage

    Phase 2

    Ages

    2 to 18

    Site

    Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois

    Locations

    25 in total

    Run by

    argenx

    See if you can join NCT04833894 on ClinicalTrials.gov

15. Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

    During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on neuromuscular junction (NMJ) transmission and fatigability in adults with Generalized Myasthenia Gravis (gMG). The investigators will also test whether a rel…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Kansas Clinical Research Center, Fairway, Kansas

    Locations

    2 in total

    Run by

    University of Missouri-Columbia

    See if you can join NCT06064695 on ClinicalTrials.gov